Clinical Trial Update: New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day [Phase 3]

View source ↗

Summary

A Phase 3 study in asthma compared a breath-actuated Symbicort inhaler to Symbicort pMDI and Budesonide pMDI over 12 weeks, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Budesonide pMDI (budesonide)
• Symbicort (budesonide/formoterol)
• Symbicort pMDI (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2014-03-11